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study the association between the presence of K-ras mutations at codon 
12 and several clinical variables in advanced NSCLC patients.
Methods: We examined 451 NSCLC patients in stage IIIB and IV, 
treated with cisplatin and docetaxel. Blood samples were collected be-
fore chemotherapy, and circulating DNA was extracted from the plasma 
using commercial adsorption columns. K-ras mutational status was 
determined by a method based in allelic discrimination with RT-PCR.
Results: Median age was 61 years [35-82] and 84% were males. 99% 
had performance status 0-1. 84% were in stage IV and 16% in stage 
IIIB. The histological subtypes were: 32% squamous cell carcinoma, 
50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferen-
tiated. 41% of the patients received second line chemotherapy. 1% 
achieved complete response (CR), 36% partial response (PR), 35% had 
stable disease (SD) and 28% progressive disease (PD). Here we pres-
ent the results of the analysis of K-ras mutations in the plasma of 165 
samples. 17 patients presented K-ras mutations (10.3%), being codon 
12 TGT in 16 patients and GTT in 1 case. Plasmatic mutations were 
found either in patients presenting squamous cell carcinoma (n=3) and 
in patients with adenocarcinoma (14). Patients with K-ras mutations in 
plasma had a median time to progression (TTP) of 2.3 months (m) [0.5-
4.6] while for wild type K-ras was 4.1 m [3.3-4.8], (p=0.9). Overall 
Survival (OS) in K-ras mutated patients was 10.1 m [4.1-15.8] and in 
wild type K-ras was 9.0 m [6.9-11.1], (p=0.6).
Conclusions: In advanced NSCLC, there were no signiﬁcant differ-
ences between patients with K-ras mutations and those with wild-type 
genotype with respect to baseline characteristics, response rates, TTP, 
or OS. Data from the rest of the cohort will be presented at the meeting.
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Background: VEGF and bFGF are among the most important an-
giogenic factors. We have explored these angiogenesis mediators in 
plasma and its prognostic signiﬁcance in advanced NSCLC.
Methods: Were enrolled 451 patients with advanced NSCLC, stages 
IIIB and IV and treated with cisplatin and docetaxel. Blood was col-
lected before chemotherapy. Plasma VEGF and bFGF levels were 
assessed by commercial ELISA (sensitivity 5 pg/ml). In parallel plasma 
from 32 age and gender-matched controls was used.
Results: Median age was 61 years (35-82) and 84% were males. 99% 
had performance status 0-1. 84% were in stage IV and 16% in stage 
IIIB. The histological subtypes were: 32% squamous cell carcinoma, 
50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferen-
tiated. 41% of the patients received second line chemotherapy. 1% 
achieved complete response (CR), 36% partial response (PR), 35% had 
stable disease (SD) and 28% progressive disease (PD). Patient’s median 
plasma levels of VEGF (20 pg/ml, [6-203]) differ signiﬁcantly (p=0.04) 
from controls (14 pg/ml, [7-53]), but in contrast bFGF levels were not 
different, 14 pg/ml [5-960] vs 10 pg/ml [6-278] respectively. There 
were not differences in patients according to histology, site of metas-
tasis and ECOG; however we could observe a tendency with stage for 
both factors: bFGF 9 pg/ml [5-24] in stage IIIB vs 15 pg/ml [6-960], 
p=0.071 and VEGF 17 pg/ml [6-145] in IIIB vs 21 pg/ml [6-203] in 
IV, p=0.086. It could not be observed any differences in response to 
therapy for both angiogenic factors; CR+PR patients presented median 
VEGF of 18 pg/ml [6-71] and bFGF 11 pg/ml [6-960] vs 20 pg/ml of 
VEGF [6-203] and 15 pg/ml of bFGF [5-395] in the SD+PD group. 
In the multivariate analysis we could not ﬁnd that VEGF and bFGF 
plasma levels were predictors for time to progression (TTP) and overall 
survival (OS).
Conclusions: VEGF but not bFGF levels in patients are signiﬁcantly 
higher in patients than in controls. In our cohort of patients with 
advanced NSCLC we have not found any relationship between serum 
VEGF and bFGF levels with stage, histology, response, site of metasta-
sis, TTP and OS.
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Background: Platinum compounds and taxanes have severe side ef-
fects in a dose and time-dependent manner, especially neurotoxicity. 
NGF plays an important role in growth and differentiation of neuronal 
components. Our goal was to study NGF levels in plasma and correlate 
it with patient’s clinico-pathologic characteristics.
Methods: The study was performed with 451 patients with advanced 
NSCLC, stages IIIB-IV and treated with cisplatin and docetaxel. 
Peripheral blood was collected before therapy. NGF were assessed by 
commercial ELISA (detection limit, 5 pg/ml). Plasma from 32 age and 
gender-matched controls was used.
Results: 91% of males, mean age 61 y [35-82]. 86 patients in ECOG 
PS 0-1 and 14 PS2. 71% in stage IV and 29% in IIIB. The histological 
subtypes were 38% squamous cell, 37% adenocarcinoma, 5% anaplasic 
large cell and 20% undifferentiated. 77.5% of the metastasis was out of 
the lung. Patients received a median of 6 cycles of chemotherapy [1-7]. 
4% presented complete response (CR), 38% partial response (PR), 25% 
stable disease (SD) and 30% progressive disease (PD). Patient’s median 
plasma levels of NGF did not differ signiﬁcantly from controls: 44 
pg/ml [6-176] vs 31 pg/ml [14-144] respectively. There were not dif-
ferences according to histology, site of metastasis and ECOG; however 
we could observe signiﬁcant differences with stage: 25 pg/ml [10-70] 
in stage IIIB vs 47 pg/ml [6-176] in stage IV (p=0.008). We could 
not observe any differences in response to therapy: CR+PR patients 
presented median NGF of 35 pg/ml [6-92] vs 39 pg/ml [10-165] in the 
SD+PD group. Splitting the cohort according to NGF median we found 
two signiﬁcantly different groups in terms of Overall Survival (OS): 
patients with NGF<44 pg/ml had a median OS of 10.9 months (m) 
[7.9-13.9] vs 7.3 m [3-11.5] for patients with NGF>44 pg/ml (p=0.03). 
In the multivariate analysis, NGF levels was not predictor for time to 
progression (TTP) and OS.
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Conclusions: NGF plasma levels did not differ in patients and controls. 
In our cohort with advanced NSCLC we have not found any relation-
ship between NGF levels with histology, response, site of metastasis 
and TTP. By contrast NGF levels are higher in those patients in stage 
IV and in those presenting poorer OS.
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Background: Cyckooxygenase 2 (Cox-2) plays a key role in progres-
sion and survival of non-small cell lung cancer (NSCLC) through 
regulation of apoptosis, angiogenesis, invasion and metastasis. We have 
previously shown that carriers of a common polymorphism in the 3`-
UTR of the Cox-2 gene have increased risk of NSCLC. 
Methods: This study comprises 257 Norwegian patients treated by 
surgery for early stage NSCLC, from 1988 to end 2003. We analysed 
lung cancer speciﬁc survival by end 2004, related to the polymorphic 
genotypes of the Cox-2 gene, tumour histology, tumour Cox-2 protein 
expression detected by immunohistochemistry, and the mutational 
status of the p53 gene. The Cox-2 3`-UTR SNP (SNP database rs5275) 
was genotyped in DNA from blood samples using the Taqman meth-
odology, p53 mutations (exons 4 - 9) were analysed in tumour DNA by 
sequencing. We used Cox-2 (CloneSP21) rabbit monoclonal antibody 
and Ultra Vision Detection system (Lab Vision) for immunostaining. 
Survival curves were assessed by Kaplan-Meier univariate analysis and 
further by Cox multiple regression analysis.
Results: The mean age was 64,2 yrs, ranging from 25 to 84 yrs, 
71%were males and 29% females. Histologically 103 (40%) were 
squamous cell carcinomas, 108 (42%) adenocarcinomas and 46 (18%) 
were large cell carcinomas. The frequency of Cox-2 genotypes was C/C 
(15,6%), CT (41,6%), T/T (42,8%). Mean survival time was reduced in 
all patients harbouring the C-allele, compared to those with the T-allele 
(survival time 3,3yrs versus 7,9yrs) (P=0,01). The C-allele was con-
ﬁrmed as a risk allele for reduced survival notably in adenocarcinoma 
(P=0,031), Lung cancer speciﬁc survival for patients with the C/C 
genotype remained poorer after adjusting for age, gender, and smoking 
in the multivariate analysis. 
In a subset of 216 patients 126 (58%) had p53 gene mutations in the 
tumours. In the remaining patients without p53 mutations (42%), the 
C-allele was clearly associated with poor survival compared to the T-al-
lele (P=0,006).
We observed slight increase in survival among patients with positive 
Cox-2 immunostaining, compared to those without positive staining. 
Patients harbouring both the C-allele and presenting positive immu-
nostaining lived slightly shorter than those with C-allele, but without 
positive immunostaining (2,6 versus 3,1 yrs), although not statistically 
signiﬁcant. We are currently studying the functional role of this SNP.
Conclusion: In patients with NSCLC the variant Cox-2 genotype 
C/C confers poor prognosis, notably in patients with adenocarcinoma. 
Patients with a wild-type p53 gene, and also harbouring the Cox-2 vari-
ant genotype C/C live shorter compared to those patients with the T/T 
genotype.
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Background: C4.4A is implied in human cancer progression. This 
glycolipid-anchoed protein is a structural homologue of the urokinase 
receptor, uPAR, which is a well-established prognostic marker in vari-
ous human cancers. Although, several pilot studies recognises C4.4A 
expression in various human tumors little is known about its prognos-
tic signiﬁcance. We therefore aim to explore the possible association 
between C4.4A expression and clinicopathological features and disease 
prognosis in patients with non-small cell lung cancer (NSCLC).
Methods: Tissue sections from 109 NSCLC patients were subjected to 
immunohistochemical staining using a polyclonal antibody that speciﬁ-
cally recognizes human C4.4A. Staining frequency and intensity was 
scored semiquantitatively and grouped into cancers with high and low 
expression of C4.4A. Kaplan-Meier survival curves were generated to 
evaluate the signiﬁcance of C4.4A expression in prognosis of NSCLC 
patients. 
Results: High C4.4A expression was observed in 44% of the speci-
mens analyzed, and it correlates with overall survival (P=0.012). 
Intriguingly, a very strong correlation was noted between high expres-
sion of C4.4A in pulmonary adenocarcinoma and survival (P<0.0001). 
Multivariate Cox regression analysis shows that high C4.4A expression 
is an independent predictor of poor disease outcome in NSCLC (risk 
ratio, 1.42; 95% conﬁdence interval, 1.09-1.86; P=0.009). Although, 
histological type is not a predictor of outcome in NSCLC, high C4.4A 
expression in adenocarcinoma is nevertheless a very strong predictor of 
poor disease outcome (risk ratio, 1.62; 95% conﬁdence interval, 1.24-
2.09; P=0.001).
Conclusions: High C4.4A expression in tumor cell is associated with 
shorter survival for NSCLC patients. Patients with pulmonary adeno-
carcinoma have a particularly poor prognosis if this histological type is 
combined with high C4.4A expression. 
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Background: Nearly half of early stage SqCLC patients (pts) will 
relapse after surgery, with distant metastasis being the main cause of 
